Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AgeX Therapeutics, Inc. (AGE)
|
Add to portfolio |
|
|
|
| Price: |
$1.57
| | Metrics |
| OS: |
38.0
|
M
| |
|
|
| Market cap: |
$59.6
|
M
| |
|
|
|
Net debt:
|
$2.03
|
B
| |
|
|
|
EV:
|
$2.09
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($7.2)
|
M
| |
|
|
|
EBIT
|
($7.4)
|
M
| |
|
|
| EPS |
($0.29)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 0.1 | 1.9 | 1.7 | 1.4 | 1.1 |
| Revenue growth | -76.4% | -92.3% | 8.1% | 23.8% | 31.1% | |
| Cost of goods sold | 0.0 | 0.0 | 0.2 | 0.2 | 0.4 | 0.0 |
| Gross profit | 0.0 | 0.1 | 1.7 | 1.5 | 1.0 | 1.1 |
| Gross margin | 61.8% | 86.8% | 91.5% | 85.9% | 73.9% | 100.0% |
| Research and development | 1.0 | 1.5 | 5.0 | 5.9 | 5.8 | |
| General and administrative | 6.0 | 6.7 | 7.4 | 8.1 | 5.6 | 0.6 |
| EBITA | -6.8 | -7.7 | -10.1 | -12.0 | -10.0 | 0.5 |
| EBITA margin | -20126.5% | -5344.4% | -541.3% | -694.5% | -714.0% | 42.3% |
| Amortization of intangibles | 0.1 | 0.1 | 0.6 | 0.6 | 0.5 | |
| EBIT | -7.0 | -7.8 | -10.7 | -12.6 | -10.4 | 0.5 |
| EBIT margin | -20514.7% | -5435.4% | -571.3% | -726.8% | -748.2% | 42.3% |
| Pre-tax income | 10.5 | 8.7 | -11.1 | -12.2 | -7.7 | 0.0 |
| Income taxes | 21.0 | 17.4 | -0.2 | 0.1 | -0.2 | 0.0 |
| Tax rate | 199.6% | 199.7% | 1.3% | | 3.0% | |
| Earnings from continuing ops | -10.5 | -8.6 | -10.9 | -12.2 | -7.5 | |
| Earnings from discontinued ops | | -0.1 | | | | |
| Net income | -10.5 | -8.7 | -10.9 | -12.2 | -7.5 | 0.0 |
| Net margin | -30947.1% | -6031.3% | -581.6% | -703.4% | -537.4% | 0.0% |
| |
| Diluted EPS | ($0.28) | ($0.23) | ($0.29) | ($0.33) | ($0.21) | |
| Shares outstanding (diluted) | 37.9 | 37.9 | 37.7 | 37.3 | 34.9 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|